Kidney function and markers of inflammation in elderly persons without chronic kidney disease: The health, aging, and body composition study  by Keller, C.R. et al.
Kidney function and markers of inflammation
in elderly persons without chronic kidney disease:
The health, aging, and body composition study
CR Keller1,2, MC Odden2, LF Fried3, AB Newman4, S Angleman5, CA Green6, SR Cummings1,7, TB Harris5
and MG Shlipak1,2,8
1Department of Medicine, University of California, San Francisco, California, USA; 2San Francisco VA Medical Center, General Internal
Medicine Section, San Francisco, California, USA; 3The Renal Section, VA Pittsburgh Healthcare System and The Renal-Electrolyte
Division, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; 4Department of Epidemiology, University of
Pittsburgh Graduate School of Public Health and the Division of Geriatric Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania, USA; 5Laboratory of Epidemiology, Demography and Biometry, Intramural Research Program, National
Institute on Aging, Bethesda, Maryland, USA; 6Division of Nephrology, Department of Medicine, University of Tennessee, Memphis, TN,
USA; 7California Pacific Medical Center Research Institute, San Francisco, California, USA and 8Department of Epidemiology and
Biostatistics, University of California San Francisco, San Francisco, California, USA
Inflammatory markers are elevated in persons with estimated
glomerular filtration rates less than 60 ml/min/1.73 m2.
As cystatin C may detect small changes in kidney function
not detected by estimated glomerular filtration rate, we
evaluated the association between cystatin C and serum
markers of inflammation in older adults with estimated
glomerular filtration rate X60. This is an analysis using
measures from the Health, Aging, and Body Composition
Study, a cohort of well-functioning adults aged 70–79 years.
Cystatin C correlated with all five inflammatory biomarkers:
C-reactive protein (r¼ 0.08), interleukin-6 (r¼ 0.19), tumor
necrosis factor a (TNF-a) (r¼ 0.41), soluble TNF receptor 1
(STNF-R1) (r¼ 0.61), and soluble TNF receptor 2 (STNF-R2)
(r¼ 0.54); Po0.0005 for all. In adjusted analyses, cystatin C
concentrations appeared to have stronger associations with
each biomarker compared with estimated glomerular
filtration rate or serum creatinine. Participants with a cystatin
CX1.0 mg/l had significantly higher levels of all five
biomarkers compared to those with a cystatin Co1.0 (mean
differences ranging 16–29%, all Po0.05). Cystatin C has a
linear association with inflammatory biomarkers in an
ambulatory elderly cohort with estimated glomerular
filtration rates X60; associations are particularly strong with
TNF-a and the STNF-R.
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C-reactive protein (CRP), interleukin-6 (IL-6), tumor
necrosis factor a (TNF-a), and other inflammatory markers
have been shown to predict cardiovascular disease.1–3
Dialysis-dependent patients have substantially increased
levels of CRP, IL-6, and TNF-a, which predict poor outcomes
in this group.4–9 Less is known about serum levels of
inflammatory markers in persons with mild to moderate
chronic kidney disease. Pecoits-Filho et al.10 evaluated 176
pre-dialysis subjects (estimated glomerular filtration rate
(eGFR) range, 1.8–16.5 ml/min/1.73 m2) and found higher
CRP and IL-6 levels in those with the lowest eGFR levels.
Similarly, Landray et al.11 found strong associations of kidney
function with CRP, fibrinogen, von Willebrand factor, and
soluble P-selectin among persons with advanced chronic
kidney disease (mean eGFR¼ 25 ml/min). Shlipak et al. and
Muntner et al.12,13 found persons with chronic kidney disease
(eGFRo60) to have elevated CRP and fibrinogen levels
compared with persons with eGFR460. Above that thresh-
old, however, eGFR was not associated with levels of these
inflammatory biomarkers. This discrepancy may exist
because eGFR is not a reliable marker for kidney function
at levels above 60 ml/min/1.73 m2.14,15
Cystatin C is a novel measure of kidney function that
appears to be at least as effective as 24-h urine calculations of
creatinine clearance for estimating GFR,16,17 and more
sensitive than eGFR for determining changes in GFR.18
Cystatin C may be particularly helpful in measuring kidney
function in persons with eGFR 460 ml/min/1.73 m2, as
eGFR does not appear to be accurate in this range.15,19
Cystatin C has also been found to be a stronger predictor of
multiple outcomes, including mortality, cardiovascular dis-
ease, and heart failure, than serum creatinine or eGFR.20–23
The relationship of cystatin C and inflammatory markers has
not been well characterized, particularly in persons without
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chronic kidney disease (eGFRX60). To that end, we
evaluated the association of cystatin C with multiple serum
inflammatory biomarkers in participants with eGFRX60 ml/
min/1.73 m2.
RESULTS
Among participants in this analysis from the Health ABC
Study, the average age was 73.5 years, mean cystatin C was
0.96 mg/l, mean creatinine was 0.96 mg/dl, and mean eGFR
was 78.6 ml/min/1.73 m2. The participants with a cystatin
CX1.0 mg/l were older, and more frequently white and male
(Table 1). Higher cystatin C concentrations were associated
with higher body mass index, lower HDL cholesterol, and
lower LDL cholesterol, a greater prevalence of hypertension,
coronary heart disease, congestive heart failure, and cere-
brovascular disease, and greater use of antiplatelet agents.
Spearman correlation coefficients between cystatin C and
all five inflammatory biomarkers were positive and statisti-
cally significant, the strongest being for TNF-a, sTNF-R1, and
sTNF-R2 (all Po0.0005; Table 2). The associations of
cystatin C with CRP, IL-6, and TNF-a concentrations
are demonstrated graphically by scatterplots and linear
regression lines in Figure 1a–c. Although correlations were
statistically significant for both serum creatinine and eGFR
with all five biomarkers, creatinine paradoxically had a
negative correlation with CRP, and eGFR had positive
correlations with CRP and IL-6. In addition, cystatin C
appeared to have stronger correlations with each biomarker
than either serum creatinine or eGFR.
In linear regression models, higher cystatin C was
significantly associated with each biomarker and had
b-coefficients that were greater in magnitude than those for
either serum creatinine or eGFR (Table 3). In contrast, linear
regression models did not show a significant association
between either serum creatinine or eGFR with CRP or IL-6.
Multivariate adjustment had very little effect on these
associations. We determined the mean level of each
biomarker among participants with cystatin C levels o1.0
and X1.0 mg/l. All mean biomarker levels were significantly
higher in participants with cystatin CX1.0 compared to
those with a cystatin Co1.0 (Figure 2, mean differences
16–29% higher for each biomarker, Po0.05 for all compari-
sons). Each of these differences remained significant after
multivariate adjustment.
Table 1 | Baseline characteristics in subjects with cystatin C above and below 1.0 mg/l
Cystatin C X1.0 mg/l (N=960) Cystatin Co1.0 mg/l (N=1429)
P-value
Mean7s.d. or N (%)
Age (years) 7473 7373 o0.0005
Black 375 (39) 686 (48) o0.0005
Female 391 (41) 816 (57) o0.0005
Ever smoker 586 (61) 775 (54) 0.001
Ever drinker 475 (50) 743 (52) 0.220
BMI (kg/m2) 27.974.8 26.974.8 o0.0005
HDL cholesterol (mmol/l) (mg/dl) 1.3270.41 (51716) 1.4770.44 (57717) o0.0005
LDL cholesterol (mmol/l) (mg/dl) 3.0870.91 (119735) 3.1970.88 (123734) 0.011
Fasting glucose (mmol/l) (mg/dl) 5.8371.78 (105732) 5.7772.05 (104737) 0.469
Diabetes 146 (15) 196 (14) 0.329
Hypertension 510 (53) 642 (45) o0.0005
Coronary heart disease 227 (24) 229 (16) o0.0005
Congestive heart failure 31 (3) 22 (2) 0.006
Cerebrovascular disease 81 (8) 91 (6) 0.055
Antiplatelets/aspirin use 370 (39) 502 (35) 0.105
Statin use 104 (11) 166 (12) 0.530
Serum creatinine (mmol/l) (mg/dl) 79712 (1.0370.16) 70712 (0.9270.16) o0.0005
Estimated GFR (ml/min/1.73 m2) 74710 82714 o0.0005
BMI, body main index; HDL, high-density lipoprotein cholesterol; GFR, glomerular filtration rate; LDL, levels of low-density lipoprotein cholesterol.
Table 2 | Spearman rank correlation coefficients of measures of kidney function and inflammatory markers
Correlation with cystatin C Correlation with creatinine Correlation with eGFR
R P-value R P-value R P-value
CRP 0.08 o0.0005 0.06 0.007 0.05 0.011
IL-6 0.19 o0.0005 0.05 0.024 0.07 0.0006
TNF-a 0.41 o0.0005 0.15 o0.0005 0.20 o0.0005
sTNF-R1 0.61 o0.0005 0.24 o0.0005 0.31 o0.0005
sTNF-R2 0.54 o0.0005 0.21 o0.0005 0.27 o0.0005
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IL-6, interleukin-6; STNF-R1, soluble TNF receptor 1; STNF-R2, soluble TNF receptor 2; TNF-a, tumor necrosis
factor a.
240 Kidney International (2007) 71, 239–244
o r i g i n a l a r t i c l e MG Shlipak et al.: Inflammation and cystatin C
For each biomarker, we tested for interactions of cystatin
C with sex and race; of these 10 tests for interaction, two were
statistically significant. In adjusted analyses, the b-coefficients
of cystatin C with log sTNF-R1 were 0.31 in black patients
compared with 0.25 in white patients (P¼ 0.005); for log
sTNF-R2, the b-coefficients were 0.27 in black patients and
0.19 in white patients (Po0.0005).
DISCUSSION
In this cross-sectional study, cystatin C had linear asso-
ciations with multiple inflammatory biomarkers in an elderly
cohort with eGFRX60 ml/min/1.73 m2. Of the biomarkers
studied, cystatin C had the strongest correlations with TNF-a
and its soluble receptors. Overall, cystatin C had the weakest
correlations with CRP, although those comparisons remained
statistically significant. Both serum creatinine and estimated
GFR were associated with TNF-a and its soluble receptors,
but not with CRP and IL-6 after multivariate adjustment.
Those participants with eGFRX60 and cystatin CX1.0 –
defined as having ‘preclinical kidney disease’ or ‘pre-CKD’ in
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Figure 1 | Associations of Cystatin C with (a) CRP, (b) IL-6 and
(c) TNF-a. (a–c) Plots of cystatin C versus log-transformed
inflammatory markers with fitted line (Po0.0005 for all).
Table 3 | Unadjusted and adjusted associations log-transformed inflammatory markers per standard deviation of cystatin C
and estimated GFR
Increase per s.d. cystatin C, eGFR, or serum creatinine
Unadjusted b-coefficient (95% CI) Adjusted b coefficient (95%CI)
Cystatin C (mg/l)
ln CRP 0.14 (0.07, 0.20)* 0.17 (0.11, 0.24)*
ln IL-6 0.23 (0.18, 0.29)* 0.19 (0.13, 0.24)*
ln TNF-a 0.33 (0.30, 0.36)* 0.30 (0.27, 0.33)*
ln sTNF-R1 0.30 (0.27, 0.32)* 0.28 (0.25, 0.30)*
ln sTNF-R2 0.24 (0.22, 0.26)* 0.23 (0.21, 0.25)*
Serum creatinine (mg/dl)
ln CRP 0.11 (0.19, 0.03)z 0.03 (0.14, 0.08)
ln IL-6 0.06 (0.00, 0.12) 0.07 (0.16, 0.01)
ln TNF-a 0.13 (0.09, 0.17)* 0.21 (0.16, 0.26)*
ln sTNF-R1 0.15 (0.11, 0.18)* 0.26 (0.21, 0.30)*
ln sTNF-R2 0.11 (0.08, 0.14)* 0.20 (0.16, 0.23)*
Estimated GFR (ml/min/1.73 m2)
ln CRP 0.06 (0.02, 0.10)z 0.02 (0.02, 0.06)
ln IL-6 0.06 (0.03, 0.09)w 0.03 (0.00, 0.07)
ln TNF-a 0.09 (0.11, 0.07)* 0.08 (0.10, 0.06)*
ln sTNF-R1 0.10 (0.12, 0.08)* 0.10 (0.12, 0.09)*
ln sTNF-R2 0.08 (0.09, 0.06)* 0.08 (0.09, 0.06)*
CRP, C-reactive protein; GFR, glomerular filtration rate ; STNF-R1, soluble TNF receptor 1; STNF-R2, soluble TNF receptor 2; TNF-a, tumor necrosis factor a.
*Po0.0005; wPo0.005; zPo0.05.
All biomarker models adjusted for age, sex, race, study site, smoking status, alcohol use, BMI, diabetes, hypertension, cerebrovascular disease, coronary artery disease, heart
failure, use of statins and/or aspirin, LDL, HDL, albumin, and glucose. STNF-R1 and sTNF-R2 models also adjusted for sampling status.
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Figure 2 | Mean values of biomarkers in subjects with cystatin
Co1.0 and cystatin CX1.0 mg/l. Error bars represent s.e.m.
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a prior study – had significantly higher levels of each
biomarker than persons with normal kidney function defined
by either eGFR or cystatin C.24
Our findings build on the information provided from
previous studies of inflammation and kidney disease. Using
eGFR, Muntner et al.13 and Shlipak et al.12 found associations
with kidney function and inflammatory biomarkers among
persons with eGFR p60, but not for eGFR X60. Using
cystatin C in subjects with advanced CKD, Landray et al.11
found higher levels of CRP and fibrinogen compared with
healthy controls. In a recent paper by Shlipak et al.,25 both
CRP and fibrinogen had linear associations with cystatin C,
but U-shaped associations with eGFR, among ambulatory
elderly persons. Our paper demonstrates the positive and
linear association between cystatin C and an extended array
of inflammatory proteins and cytokines among persons with
eGFR X60.
The most likely explanation for the apparently stronger
association of inflammatory biomarkers with cystatin C than
with eGFR or serum creatinine is that declines in kidney
filtration are associated with increased levels of inflammatory
biomarkers, and that cystatin C approximates actual GFR
better than creatinine-based formulae, particularly when
eGFR X60. Although the exact mechanism of inflammatory
marker elevation in kidney disease remains unclear, intact
kidney function may be essential for adequate removal of
inflammatory markers from the bloodstream. Biomarkers
are, in general, small by weight and may be filtered at the
glomerulus in subjects with normal kidney function. The
approximate molecular weights for the biomarkers in our
study are as follows: CRP, 115 kilodaltons (kDa); IL-6,
26 kDa; TNF-a, 17 kDa monomers, and 54 kDa trimers;
sTNF-R1, 30 kDa; sTNF-R2, 33 kDa.26–28 Although there
appears to be only a moderate connection in this study
between the size of the biomarker and its correlation with
kidney function, those most highly associated with kidney
function in our study, namely TNF-a, sTNF-R1, and sTNF-
R2, are all molecules under 55 kDa. Furthermore, it has been
shown that TNF-a is predominantly cleared by the kidney,
wheras IL-6 and CRP are mainly cleared by the liver.29–31
Similarly, cystatin C (13 kDa) is freely filtered at the
glomerulus, which likely leads to its strong association with
the inflammatory biomarkers that are renally cleared.32
An alternative hypothesis for the association between
cystatin C and inflammatory biomarkers is that cystatin C
itself may be a regulator of inflammation. Cystatin C is a
potent cysteine protease inhibitor that has been demons-
trated in vitro to regulate certain aspects of immune
function.33 Cystatin C is also upregulated in hyperthyroid-
ism, a condition that has been associated with modified
cytokine profiles.34,35 In our study, we are unable to
determine the degree to which the association of cystatin C
with inflammatory biomarkers was caused by some direct
link to immune regulation.
In addition to the significant association of cystatin C with
all five inflammatory biomarkers, both serum creatinine and
eGFR were associated with TNF-a, sTNF-R1, and sTNF-R2 in
persons with eGFR X60. While this seems to support the
concept that serum elevations in TNF-a and its receptors are
a function of their clearance by the kidney, it is also possible
that TNF-associated inflammation may promote the pro-
gression of kidney disease. Limited data from other
experiments support this hypothesis: in murine models, for
example, TNF-a knockout mice were relatively protected
from induced glomerular injury.36 Elucidation of the patho-
genic role for TNF-a in kidney-specific inflammatory path-
ways would help to clarify the importance and direction of
the association between TNF biomarkers and kidney
function.
Our study has several limitations. We are unable to
determine either the direction of association or the causal
pathway given the cross-sectional design of our study. For
example, it is possible either that systemic inflammation
leads to kidney dysfunction, or that decreased kidney
filtration results in elevated inflammatory biomarkers, or
that both contribute to the observed findings. Furthermore,
our data were obtained from an older population of white
and black subjects; the results from this group may not be
generalizable to a younger population or to persons of other
races and/or ethnicities. In addition, a more direct measure-
ment of GFR, such as inulin clearance, was not used in this
study as a gold standard for comparison. We also did not
calibrate creatinine in this study with the Cleveland Clinic
standard, as in the modification of diet in renal disease
study.37 However, arithmetic calibration of creatinine would
not have affected the overall findings with eGFR and each
inflammatory marker. Moreover, we lacked measures of urine
albumin excretion, which may also correlate with inflamma-
tory biomarkers in elderly persons without CKD.
Finally, the extent to which other covariates influence the
relationship between cystatin C and glomerular filtration rate
remains controversial in the literature. On the one hand, a
recent paper by Rule et al.38 found that age and sex did not
influence the prediction of GFR by a cystatin C-based
equation in persons with CKD. However, in a population-
based study, Knight et al.39 found that cystatin C concentra-
tions were independently associated with older age, male
gender, greater weight, greater height, and cigarette smoking,
even after adjustment for measured creatinine clearance.
Therefore, cystatin C may potentially be influenced by these
covariates independent of their effects on GFR. If cystatin C
concentrations are to be used as a clinical marker of kidney
function, then future studies will be needed to understand
comprehensively its susceptibility to bias from non-renal
factors.
In summary, we found that multiple inflammatory
biomarkers were highly associated with cystatin C in persons
with eGFR X60 ml/min/1.73 m2. In contrast, higher creati-
nine levels and lower eGFR were not associated with
elevations of CRP and IL-6 levels in this population. These
findings suggest that serum cystatin C is a more sensi-
tive marker than eGFR for detecting the association of
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inflammation with kidney disease, especially among persons
without chronic kidney disease.
MATERIALS AND METHODS
Study design and population
The Health ABC Study is a prospective cohort study designed to
evaluate the relationships between body composition and weight-
related health conditions with incident functional limitation among
well-functioning black and white adults aged 70–79. Three thousand
and seventy-five persons completed a baseline evaluation and were
enrolled between April 1997 and June 1998. Serum cystatin C and
creatinine levels were obtained in 3043 participants (99%).
Participants were recruited from two sites: Pittsburgh, Pennsylvania,
and Memphis, Tennessee. White subjects were recruited from a
random sample of Medicare beneficiaries; black subjects were
recruited from all age-eligible subjects within the regions. Parti-
cipants were eligible if they reported no difficulty walking a quarter
mile, climbing 10 steps, ambulating without assistive devices, and
performing basic activities of daily living. Subjects were excluded
from the study if they reported having a life-threatening illness, had
a history of active cancer in the 3 years before the study, did not plan
to remain in the geographic area for at least 3 years, or were
participating in another study involving modification of eating or
exercise behaviors. In this analysis, participants were also excluded if
they had an eGFR o60 ml/min/1.73 m2. All participants gave
written informed consent that was approved by institutional review
boards at both clinical sites.
Serum measurements
Serum and EDTA plasma were drawn in the morning after an
overnight fast during the initial visit and stored at 701C. Cystatin
C was measured using a particle-enhanced immunonepholometric
assay (N Latex Cystatin C) with a BNII nephelometer on plasma
specimens (Dade Behring Inc., Deerfield, IL).40 Polystyrene particles
coated with monoclonal antibodies that agglutinate in the presence
of antigen (cystatin C) cause an increase in the intensity of scattered
light in proportion to the amount of cystatin C in the sample. The
assay range is 0.195–7.330 mg/l, with the reference range for young,
healthy individuals reported as 0.53–0.95 mg/l. Intra-assay coeffi-
cients of variation range from 2.0–2.8% and inter-assay coefficients
of variation range from 2.3 to 3.1%. Serum creatinine levels were
measured at the time of the 1997–1998 annual visit using
colorimetry with a Johnson & Johnson Vitros 950 analyzer (New
Brunswick, NJ). Estimated GFR was calculated using the creatinine-
based abbreviated modification of diet in renal disease (MDRD)
equation.41
All biomarkers were measured by enzyme-linked immuno-
sorbent assay (CRP: Calbiochem, San Diego, CA; all others: R&D
Systems, Minneapolis, MN). The detectable limits for each
inflammatory marker are reported as follows: 0.08 mg/ml for
C-reactive protein (using the World Health Organization’s First
International Reference Standard), 0.18 pg/ml for tumor necrosis
factor alpha (using the HSTA50 kit), 0.10 pg/ml for interleukin-6
(using the HS600 Quantikine kit), 3 pg/ml for soluble tumor
necrosis factor receptor-1 (sTNF-R1, using the DRT100 kit), and
1 pg/ml for soluble tumor necrosis factor receptor-2 (sTNF-R2,
using the DRT200 kit). Blind duplicate analyses on 150 serum
samples for CRP, TNF-a, and IL-6 showed an average interassay
coefficient of variation of 8.0, 15.8, and 10.3%, respectively.
Biomarkers were measured in varying subsamples of the cohort:
CRP, N¼ 2383; TNF-a, N¼ 2249; IL-6, N¼ 2283; sTNF-R1,
N¼ 1147; sTNF-R2, N¼ 1144. Data for the STNF-R1 AND -R2
were measured in a total of 722 controls and randomly selected
subjects, as well as 425 cases who developed severe functional
impairment and were included in a separate case–control study.
Other baseline variables that were evaluated as potential
confounders included demographic characteristics (age, sex, race,
study site), lifestyle parameters (smoking history, defined as ever
(current or former) or never; alcohol use, defined as X1 drink per
week; body mass index, measured at the baseline visit); comorbid-
ities (diabetes, defined by the use of hypoglycemic medications, by
self-report, or by a fasting plasma glucose X126 mg/dl; hyperten-
sion, defined by the use of antihypertensive medications or by self-
report; cerebrovascular disease, coronary artery disease, heart
failure, all determined by self-report); medications (statins and
aspirin, all brought by the patient at the baseline visit and recorded);
and serum chemistries (levels of low-density lipoprotein cholesterol
(LDL), high-density lipoprotein cholesterol (HDL), albumin, and
glucose, all measured using colorimetry with a Johnson & Johnson
Vitros 950 analyzer (New Brunswick, NJ)). LDL was calculated using
the Friedewald equation.42
Statistical analysis
We compared baseline characteristics among participants with
cystatin C concentrations X1.0. with those o1.0 mg/l using either
t-tests or w2 tests, where appropriate. This cutpoint was chosen
based on a recent study that defined elderly persons with eGFR
X60 ml/min and cystatin C X1.0 mg/l as having ‘preclinical kidney
disease’.24 We calculated Spearman correlation coefficients for
cystatin C, serum creatinine, and eGFR with each of the biomarkers,
and we plotted the distribution of cystatin C against each of the log-
transformed inflammatory markers and fitted a linear regression
line. We checked for departure from linearity by plotting the stand-
ardized residuals from the linear model against log-transformed
fitted values of each biomarker.
To control for the influence of potential confounding variables,
we used multivariate linear regression to determine if cystatin C,
serum creatinine, and eGFR were independently associated with
each of the log-transformed biomarkers. All covariates listed in
Table 1 were entered into the model based on their hypothesized role
as potential confounders owing to their known associations with
either kidney disease or inflammation. In addition, models for
sTNF-R1 and sTNF-R2 were adjusted for sampling by adding case
status as a variable in the regression analyses.
The cystatin C cutpoint of 1.0 mg/l was used to define two
groups, both with eGFR X60 ml/min.24 The mean levels of each
biomarker in each group were presented, and a two-sample t-test
was used to test for significance between groups.
We tested for a significant interaction between race and sex with
cystatin C in all adjusted regression models. We used STATA 8.0
(Statacorp LP, College Station, TX) for all analyses.
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